FDA Alert
FDA Alert
04/22/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA previously approved lisocabtagene maraleucel as a second-line treatment option for adult patients with large B-cell lymphoma in June 2022.
04/22/2024
FDA ALERT
FDA ALERT
01/26/2024

Anthony Calabro, MA

Anthony Calabro, MA
The FDA approved pirtobrutinib for adults with either chronic lymphocytic leukemia or small lymphocytic lymphoma who have received at least two prior lines of therapy.
01/26/2024
FDA
FDA
08/21/2020
A drug that was first approved in 2009 for the treatment of chronic lymphocytic leukemia has now been approved by the FDA to treat relapsing forms of multiple sclerosis.
08/21/2020